# Quest Diagnostics **Source:** https://geo.sig.ai/brands/quest-diagnostics **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** questdiagnostics.com **Last Updated:** 2026-04-14 ## Summary Nation's largest clinical lab with 230M tests/year; $9.8B FY2024 revenue; liquid biopsy and genomic oncology testing growth; consumer-direct app strategy; competes with Labcorp. ## Company Overview Quest Diagnostics is the nation's leading provider of diagnostic information services, founded in 1967 as MetPath and headquartered in Secaucus, New Jersey, trading on NYSE (DGX). The company processes approximately 230 million clinical laboratory tests annually, serving patients through approximately 2,250 patient service centers, physician offices, hospitals, and health plans across the United States. For FY2024, Quest generated approximately $9.8 billion in total revenues under CEO James Davis, who succeeded Steve Rusckowski in 2022 and has accelerated the company's strategy of expanding consumer access, digital connectivity with ordering physicians, and advanced specialty testing capabilities in oncology, genetics, and infectious disease. Quest's network of regional laboratories and patient service centers creates geographic density that enables same-day or next-day specimen processing for most clinical testing, with routine tests including blood counts, metabolic panels, lipid profiles, and urinalysis generating high-volume, lower-margin base revenue. Advanced diagnostics—including genomic sequencing for hereditary cancer risk, liquid biopsy (Signatera), advanced cardiovascular testing (QHeartHealth), and toxicology—represent the higher-margin growth opportunities where Quest is investing in laboratory technology and clinical bioinformatics. The company's 2022 acquisition of Haystack Oncology and multiple hospital outreach laboratory acquisitions in 2023-2024 expand its oncology testing footprint. In 2025-2026, Quest competes primarily with Labcorp (LH) in national commercial laboratory testing and with hospital laboratory systems for in-patient and affiliated outpatient testing. Value-based care models create headwinds for traditional fee-for-service laboratory testing volumes, while the shift toward at-home testing (as demonstrated by COVID-19 at-home tests) creates both threats and opportunities for Quest's consumer-direct strategy. Quest's app-based test ordering, result delivery, and direct-to-consumer health monitoring capabilities are designed to build consumer loyalty beyond physician referrals. The federal No Surprises Act and commercial payer reimbursement pressure on laboratory test rates create ongoing margin management challenges across routine testing categories. ## Frequently Asked Questions ### What is Quest Diagnostics? Quest Diagnostics is America's leading provider of diagnostic information services and a Fortune 500 company operating one of the broadest networks for clinical laboratory testing in the United States. The company serves approximately one in three adult Americans annually, offering a comprehensive menu of 3,500+ laboratory tests ranging from routine blood work to advanced genomic diagnostics, oncology screening, and AI-powered pathology solutions across the United States, Puerto Rico, Mexico, and Brazil. ### When was Quest Diagnostics founded? Quest Diagnostics traces its origins to 1967 when Dr. Paul A. Brown founded Metropolitan Pathology Laboratory, Inc. with a $500 loan from his father-in-law. The company was renamed MetPath, Inc. in 1969, later became Corning Clinical Laboratories under Corning ownership, and emerged as the independent publicly-traded Quest Diagnostics in 1996-1997 through spinoff from Corning Inc. ### Where is Quest Diagnostics headquartered? Quest Diagnostics is headquartered in Secaucus, New Jersey. The company operates approximately 2,200 patient service centers across the United States and maintains operations in Puerto Rico, Mexico, and Brazil, serving over 650,000 physician and hospital accounts. ### Who are Quest Diagnostics' customers and target market? Quest serves a diverse customer base including individual patients (reaching one in three adult Americans annually), physicians and healthcare providers (650,000 accounts), hospitals and health systems, employers (for drug screening and workplace health programs), health insurance plans (over 90% of in-network lives nationwide), and direct-to-consumer customers through QuestDirect. The company provides services across all disease areas and patient demographics. ### What is Quest Diagnostics' revenue and market position? Quest reported fiscal 2024 revenues of $9.87 billion, up 6.7% from 2023, with the Diagnostic Information Services segment generating $9.614 billion (97% of total revenue). The company projects fiscal 2025 revenues between $10.70 billion and $10.85 billion, representing 8.4%-9.9% growth. Quest is one of two dominant national independent clinical laboratories in the U.S. alongside Labcorp, together managing roughly one-fifth of total U.S. specimen volume. ### What makes Quest Diagnostics different from competitors? Quest differentiates through its unparalleled scale and network (2,200+ patient service centers, 650,000 provider accounts, serving one in three American adults), extensive test menu (3,500+ tests), leadership in Advanced Diagnostics ($900 million in 2024 sales), strategic partnerships (Google Cloud for AI, Epic for workflow integration, Guardant Health for cancer screening), and comprehensive health plan access (90%+ in-network coverage nationwide). The company combines operational excellence with cutting-edge innovation in AI-powered diagnostics and precision medicine. ### Who are Quest Diagnostics' main competitors? Quest's primary competitor is Laboratory Corporation of America (Labcorp), the other dominant national independent clinical laboratory. Together, Quest and Labcorp manage approximately one-fifth of total U.S. specimen volume. The company also competes with hospital-based laboratories (which hold the largest market share in the fragmented U.S. clinical laboratory market), regional independent laboratories, and specialty diagnostic companies in specific testing categories like genomics and pathology. ### Who is Quest Diagnostics' CEO? James E. (Jim) Davis serves as Chairman, CEO, and President of Quest Diagnostics. Davis became CEO and President on November 1, 2022, succeeding Steve Rusckowski, and was elected Chairman of the Board effective April 1, 2023. Prior to Quest, Davis was CEO of InSightec, Inc. and spent two decades in senior management at General Electric's aviation and healthcare businesses, including leading GE's MRI business for five years. ### What is Quest Diagnostics' growth strategy? Quest's growth strategy focuses on: (1) Advanced Diagnostics expansion (molecular, oncology, neurology solutions like AD-Detect and Haystack MRD); (2) Strategic acquisitions (eight completed in 2024 including $1B LifeLabs in Canada); (3) Health plan access expansion (90%+ in-network lives through Elevance Health and Sentara partnerships); (4) Technology innovation (Google Cloud AI, Epic collaboration via Project Nova); (5) New testing services (approximately 50 innovative tests introduced in 2024); and (6) Strategic partnerships (Guardant Shield cancer screening, MD Anderson multi-cancer blood test development). ### How can I contact Quest Diagnostics? You can visit Quest Diagnostics' official website at www.questdiagnostics.com to find patient service center locations, schedule appointments, access test results, and find contact information for specific services. The company's headquarters is located in Secaucus, New Jersey, with approximately 2,200 patient service centers nationwide for convenient access to testing services. ### Is Quest Diagnostics hiring? Yes, Quest Diagnostics actively recruits talent across clinical laboratory roles, healthcare services, technology and IT, sales and business development, and corporate functions. The company employs approximately 45,000-50,000 people and maintains 11 Employee Business Networks (EBNs) open to all employees, focusing on culture and belonging with programs supporting enriching culture, expanding opportunity, and elevating belonging. Career opportunities are available at www.questdiagnostics.com/careers. ### What are Quest Diagnostics' latest developments? Recent milestones include: completing eight acquisitions in 2024 including LifeLabs ($1B, Canada expansion) and PathAI lab assets (AI/digital pathology); reporting fiscal 2024 revenue of $9.87B (up 6.7% YoY) with Q4 revenue of $2.62B (up 14.5%); expanding health plan access to 90%+ in-network lives through Elevance and Sentara partnerships (January 2025); announcing Epic collaboration for Project Nova (September 2025); receiving FDA breakthrough designation for Haystack MRD; publishing AD-Detect Alzheimer's blood test study showing 91% sensitivity/specificity; and announcing Guardant Shield colorectal cancer screening collaboration. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*